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Vitiligo is a common skin disease characterized by
the presence of well circumscribed, depigmented,
milky white macules devoid of identi®able melano-
cytes. Although the detection of circulating anti-
melanocytic antibodies and of in®ltrating lympho-
cytes at the margin of lesions supports the view that
vitiligo is an autoimmune disorder, its etiology
remains unknown. In particular, it is still a matter of
debate whether the primary pathogenic role is exerted
by humoral or cellular abnormal immune responses.
In this study, the presence of speci®c cytotoxic T
lymphocyte responses against the melanocyte differ-
entiation antigens Melan-A/MART1, tyrosinase, and
gp100 in vitiligo patients have been investigated by
the use of major histocompatibility complex/peptide
tetramers. High frequencies of circulating melano-
cyte-speci®c CD8+ T cells were found in all vitiligo
patients analyzed. These cells exerted anti-melano-
cytic cytotoxic activity in vitro and expressed skin-
homing capacity. In one patient melanocyte-speci®c
cells were characterized by an exceptionally high
avidity for their peptide/major histocompatibility
complex ligand. These ®ndings strongly suggest a
role for cellular immunity in the pathogenesis of
vitiligo and impact on the common mechanisms of
self tolerance. Key words: cytotoxic T lymphocytes/
human/melanocyte differentiation antigen/vitiligo. J Invest
Dermatol 117:326±332, 2001
V
itiligo is a relatively frequent skin disease (1% of the
general population) characterized by the presence of
depigmented macules and patches as a consequence
of local melanocyte loss. Although its etiology
remains unknown, the detection of circulating anti-
melanocytic antibodies (Naughton et al, 1983; Betterle et al, 1984;
Song et al, 1994; Cui and Bystryn, 1995; Kemp et al, 1997;
Merimsky et al, 1998; Okamoto et al, 1998) and of lymphocytic
in®ltration at the margin of lesions (al Badri et al, 1993b; Le Poole
et al, 1996) in most patients with vitiligo strongly supports the view
that vitiligo is an autoimmune disorder. In addition, the most
effective treatments that induce repigmentation, such as psoralen
and ultraviolet A or topical steroids (Pruvot-Sentous et al, 1992;
Mosher et al, 1999), suppress immune reactivity (Mandel et al,
1997; Halder and Young, 2000), suggesting that their immuno-
suppressive mechanisms interfere with the mechanism that leads to
damage of melanocytes (Bystryn, 1997; Mahmoud et al, 1998).
The pathogenic role of melanocyte-speci®c autoantibodies in
vitiligo is still a matter of debate. Although these antibodies have
been shown to be able to damage pigment cells both in vitro (Cui
et al, 1993) and in vivo (Gilhar et al, 1995), more recently it has been
reported that speci®c autoantibodies for the melanocyte differen-
tiation antigen tyrosinase are present at a low frequency in the sera
of vitiligo patients (Kemp et al, 1997), and that such autoantibody
titers may be found both in vitiligo-like depigmentation (mela-
noma-associated hypopigmentation) and in healthy controls
(Merimsky et al, 1996). This suggests that other mechanisms may
lead to melanocyte loss.
The patchy, rather than generalized, distribution of cutaneous
depigmentation and the most frequent symmetrical distribution of
lesions support the hypothesis that autoimmune melanocyte
damage is induced by clones of lymphocytes with af®nities for
speci®c areas of skin, rather than by anti-melanocytic autoanti-
bodies (al Badri et al, 1993a). Evidence for the involvement of
cellular immunity in the etiopathogenesis of vitiligo is further
provided by rare cases of in¯ammatory vitiligo (Le Poole et al,
1996) and by the interesting, although isolated, observation of
frequent skin-homing melanocyte-speci®c cytotoxic T lympho-
cytes (CTL) in some vitiligo patients (Ogg et al, 1998).
Several melanocyte glycoproteins have been shown to be
antigenic; namely, the melanocyte differentiation antigens Melan-
A/MART1, the gp100, and the tyrosinase (Chen et al, 1995;
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Marincola et al, 1996; Boon and Old, 1997; Kageshita et al, 1997;
Van den Eynde and van der Bruggen, 1997). They are consistently
expressed in normal melanocytes and are highly expressed in
melanoma, where speci®c CTL-mediated immune reactivity has
been demonstrated. It is therefore conceivable that immunodomin-
ant antigens are similar in melanoma and vitiligo and that a
melanocyte-speci®c CTL response can play a part in the disappear-
ance of epidermal melanocytes in vitiligo.
If peripheral autoreactive T cells speci®c for melanocyte-
differentiation antigens exist, this implies an incomplete self
tolerance achievement. Numerous studies now support the view
that the fate of self speci®c T cells depends on the avidity of T cell
receptor±self ligand interactions within the thymus (central toler-
ance) or in the periphery (peripheral tolerance) (Kappler et al, 1987;
Kisielow et al, 1988; Guerder and Matzinger, 1992; Surh and
Sprent, 1994). The processes of positive and negative selection are
based on the stability of the interaction between T cell receptor and
peptide/major histocompatibility complex. Positive selection
occurs after short interactions (low avidity), whereas negative
selection is thought to be a result of more prolonged interactions
(high avidity) leading to activation-induced cell death (Williams
et al, 1999; Kersh et al, 1998). Therefore, only antigen-speci®c T
cells characterized by a low-avidity phenotype for self antigens are
expected to remain unaffected by intrathymic and/or extrathymic
deletion (Liu et al, 1995; Morgan et al, 1998; Lee et al, 1999; Wang
et al, 1999).
In this study, we sought to investigate the presence of speci®c
CTL against Melan-A/MART1, tyrosinase and gp100 antigens in
vitiligo patients by the use of major histocompatibility complex/
peptide tetramers and asked whether these cells could play a part in
melanocytic destruction.
MATERIALS AND METHODS
Patients Fourteen patients with nonsegmental vitiligo (nine females
and ®ve males) were included in this study. The patients did not receive
any treatment for at least 3 mo prior to examination. Surface area
involvement was estimated according to the ``rule of nines''. Two
patients had associated autoimmune disease (thyroiditis). Peripheral blood
samples of 30 ml from each patient had been obtained after signed
informed consent. Six HLA-A*0201-positive blood donors were used as
controls.
HLA-DNA typing Molecular typing for HLA-A genes was performed
by polymerase chain reaction-sequence-speci®c primers technique. High-
resolution typing was performed in all the HLA-A*02 positive patients,
with polymerase chain reaction±sequence-speci®c primers employing a
speci®c set of primers dry solution (Olerup et al, 1993). Nine patients
turned out to be HLA-A*0201-positive.
Synthetic peptides The following peptides were purchased from
Neosystem (Strasbourg, France): A27L (an analog of the Melan-A/
MART126±35 epitope carrying a substitution of Ala for Leu at position 2
from the NH2 terminus, ELAGIGILTV) (Valmori et al, 1998), gp100-
209M (an analog of the G9209 epitope carrying a substitution of Thr
for Met at position 2, IMDQVPFSV) (Parkhurst et al, 1996) and
tyrosinase1±9 (MLLAVLYCL) (Van Wolfel et al, 1994). All peptides were
> 90% pure as indicated by analytical high-performance liquid
chromatography. Lyophilized peptides were diluted in dimethyl sulfoxide
and stored at ±20°C.
Tetramers Production of major histocompatibility complex/peptide
tetramers has been described in detail (Altman et al, 1996). Brie¯y,
recombinant HLA-A2 heavy chain and b2-microglobulin heterodimers
were produced as inclusion bodies in Escherichia coli XA90F¢LacQ1. After
extensive washing, inclusion bodies were dissolved in 8 M urea and
HLA monomeric proteins were refolded in the presence of 10±40 mg of
the respective peptides by dilution in 100 mM Tris, 0.4 M Arginine,
2 mM ethylenediamine tetraacetic acid, pH 8.0, 0.5 mM oxidized
glutathione, 5 mM reduced glutathione and protease inhibitors.
Monomers were concentrated, dialyzed against Tris 10 mM, pH 8.0, and
biotinylated with 6 mg per ml of BirA enzyme for 4 h at 30°C.
Biotinylated complexes were dialyzed and puri®ed by ion exchange
chromatography (monoQ, Pharmacia France, St Quentin en Yvelines,
France) to remove free biotin. Tetramerization was achieved by adding
phycoerythrin (PE) -conjugated streptavidin (Immunotech, a Beckman-
Coulter company, Marseille, France) at a 4:1 ratio, and controlled by gel
®ltration on a Superdex 200 (Pharmacia France).
Flow cytometry Cells were stained with PE-labeled tetramers
(0.5 mg/106 cells) for 15 min at 37°C; after two washes, indirect double-
staining was performed using anti-human CD8 monoclonal antibody
(OKT8, IgG2a) and ¯uorescein isothiocyanate (FITC) -labeled goat anti-
mouse IgG2a (Southern Biotechnology Associates, Birmingham, AL) as
second antibody. The speci®city of each tetramer was con®rmed by
staining CTL lines or clones speci®c for HLA±A2 in association with the
peptide of interest (not shown). To minimize background staining,
tetramers were titrated and used at the lowest concentration that still
gave a discernible population. A stringent gate for tetramer+ cells, which
did not include tetramerlow cells, was always set to avoid overestimation
of the positive cells. The limit of detection of each tetramer had been
previously determined to be 0.04% of CD8+ T cells for A2/Melan-A
and A2/tyrosinase, and 0.06% of CD8+ T cells for A2/gp100 (Palermo
et al, 2001). Triple staining with A2/Melan-A tetramerPE, anti-
CD45RACYC (IgG2b; Becton-Dickinson, Mountain View, CA) and
either anti-CD45ROFITC (IgG2a; Caltag Laboratories, Burlingame, CA)
or anti-CD56FITC (IgG2a; Southern Biotechnology Associates), were
performed to assess the naive/memory phenotype of tetramer+ cells.
FITC-labeled anti-cutaneous lymphocyte-associated antigen (anti-CLA)
monoclonal antibody HECA-452 (rat IgM; Becton-Dickinson) was used
to stain CTL clones for 30 min on ice. Cells were analyzed on a
FACScalibur (Becton-Dickinson). Data were analyzed using the
CellQuest software. Lymphocytes were gated by forward and side scatter
pro®le. Dead cells were excluded by propidium iodide staining.
T cell lines and clones For the generation of peptide-speci®c T cell
lines, peripheral blood mononuclear cells (PBMC) from patients were
isolated by Ficoll centrifugation (Ficoll-Paque; Amersham Pharmacia
Biotech, Uppsala, Sweden) and monocyte-depleted by exclusion of
plastic adherent cells. We cultured 105 per well PBMC in complete
RPMI medium supplemented with 5% human serum, in the presence of
105 peptide-pulsed T2 cells. T2 cells are HLA-A*0201 human lymphoid
cells that are defective in antigen processing but effectively present
exogenously supplied peptides (Ljunggren et al, 1990). T2 loading was
done in serum-free medium (X-VIVO 15, BioWhittaker, Walkersville,
MD) using 2 mg per ml of A27L and 3 mg per ml of gp100-209M
peptides following overnight incubation at 37°C. Low-dose (25 U per
ml) interleukin-2 was added on day 5. For the cloning experiments, cells
were plated at 0.3 cells per well in complete RPMI medium in the
presence of irradiated PBMC (5 3 105 cells per ml), 2 mg per ml
phytohemagglutinin and 250 U per ml recombinant interleukin-2.
Proliferating clones were expanded in complete RPMI medium
supplemented with 5% human serum and 500 U per ml recombinant
interleukin-2.
Cytotoxicity analysis Peptide-speci®c T cell lines and clones were
assayed for speci®c lysis using either peptide-pulsed T2 cells or two
HLA-matched melanoma cell lines (501 mel and 213 mel, kind gifts of
L. Rivoltini, Cancer Immunotherapy Unit, Istituto Nazionale Tumori,
Milano) in a standard 4 h chromium release assay. Brie¯y, 106 target cells
were labeled with 200 mCi 51Cr for either 1.5 h (melanoma cells) or
15 h (T2 cells). T2 cells were pulsed with 3 mg per ml Melan-A/
MART1 peptides for 30 min at room temperature. T2 cells pulsed with
a HLA-A*0201 restricted, irrelevant peptide (gp100-209M) were used in
each assay as a negative control at the same concentration as the relevant
peptides. We plated 103 target cells per well and effector cells were
added to give ®nal E/T ratios ranging between 50 : 1 and 3 : 1. After
4 h at 37°C, 25 ml supernatant was collected, seeded in Lumaplate 96
solid scintillation plates (Packard Instruments Company, Meriden, CT)
and counted in a b counter. The percentage of speci®c lysis was
calculated as: 100 3 (experimental release ± spontaneous release)/
(maximum release ± spontaneous release). Spontaneous release was
assessed by incubating target cells in the absence of effectors and
maximum release was determined in the presence of 1% Nonidet P-40
detergent (BDH Biochemicals, Poole, U.K.).
Avidity Titration curves over a wide range of peptide concentrations
(1.2 3 10±8 M to 1.5 3 10±12 M) were generated and the avidity of the
different clones was determined as the concentration of peptide required
to obtain half maximal lysis ([nM] 50%) of target cells in standard
cytotoxicity tests at a low E/T cell ratio (5 : 1).
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Statistical analysis The Mann±Whitney test was used to compare
differences in the percentages of tetramer+ cells found in vitiligo patients
vs healthy donors.
RESULTS
High frequencies of circulating melanocyte-speci®c CD8+
T lymphocytes in vitiligo patients To assess whether
melanocyte-speci®c CD8+ T lymphocytes are commonly present
in vitiligo patients, we synthesized three ¯uorescent HLA-A2
tetramers complexed with peptides derived from melanocyte
differentiation antigens: A2/Melan-A, A2/tyrosinase, and A2/
gp100. We used these three tetramers to stain PBMC from 14
vitiligo patients directly ex vivo, without any antigen-speci®c
stimulation. Clinical and immunogenetic characteristics of the
patients are presented in Table I. High numbers of both Melan-A/
MART1- and tyrosinase-speci®c cells were detected in all nine
HLA-A*0201 patients (Table II). Detection was dependent on the
expression of HLA-A*0201, as none of ®ve A*0201-negative
vitiligo controls had detectable tetramer+ cells ex vivo (not shown).
The frequency of A2/Melan-A tetramer+ cells varied between
0.07% and 0.28% (mean 0.14%) of the total CD8+ population, and
the frequency of A2/tyrosinase-positive cells between 0.10% and
0.22% (mean 0.16%) (Table II and Fig 1). On the contrary, no
gp100-speci®c CD8+ T cells could be observed directly ex vivo by
tetramer staining (Table II). This could mean either that CD8+
cells speci®c for the peptide were not present or that their
frequency was below the detection limit of tetramer staining. To
discriminate between these two possibilities, PBMC from four
selected patients were stimulated at 3 wk intervals using antigen-
presenting cells (T2 cells) loaded with gp100-209M peptide. On
day 8 after each stimulation cycle, recovered cells were monitored
for the presence of CD8+/tetramer+ cells. After three stimulation
cycles a signi®cant enrichment of tetramer+ cells was obtained in
two of 11 cell lines established from patient PSA (from 0.04% to
4.3% tetramer+ cells) (Fig 2), but from none of 11 lines established
from patient MBO, six lines established from patient LPA and three
lines established from patient TSC (not shown). These ®ndings
support the occasional presence of gp100-speci®c CTL in vitiligo
patients, but are indicative of a low precursor frequency of these
cells.
In the light of the recent evidence that Melan-A/MART1-
speci®c CD8+ cells exist also in some HLA-A*0201 normal
individuals (Pittet et al, 1999), PBMC from six A*0201-positive
normal donors were analyzed with the A2/Melan-A tetramer. In
two cases we could detect discrete populations of tetramer+ cells,
which represented 0.07 and 0.13% of the total CD8+ T cell
population. Whereas naive T cells represented a variable proportion
of the patients' tetramer+ lymphocytes (between 36% and 60%,
mean 47.4%, data not shown), virtually all the Melan-A-speci®c
cells found in these two healthy donors displayed a naive phenotype
(80% and 90% were CD56± CD45RAhigh CD45RO±, data not
shown), in agreement with previous data (Pittet et al, 1999; Dunbar
et al, 2000). In all the other healthy donors tested tetramer+ cells
were detected at frequencies close to or below our estimated
detection limit for A2/Melan-A tetramer staining (Table II,
Fig 1). Overall, the frequency of tetramer+ cells found in the
peripheral blood of healthy controls appeared to be signi®cantly
lower than that found in vitiligo patients (p = 0.015). In view,
however, of the smallness of the compared populations (nine
patients vs six healthy donors) we consider this statistical result a
strong indication, yet not a formal demonstration, of the difference
between these two groups.
Anti-melanocytic cytotoxic activity of tetramer+ cells from
vitiligo patients We established several Melan-A/MART1-
speci®c cell lines from three patients and two donors through
repeated PBMC antigen-speci®c stimulation in vitro. Ten of 11 cell
Table I. Clinical and immunogenetical ®ndings of the patients
Patient Sexa Duration (y) Courseb Disease extension (%) Associated diseases HLA-A alleles
1 RSA M 21 Stable Hands, penis (13%) Hypertension, NIDDMc 0201
2 PSA F 20 Stable Diffuse (80%) No 0201
3 TSC F 25 Stable Abdomen, feet (18%) No 0201,11
4 SRI M 10 Progression Diffuse (80%) Psoriasis 0201,11
5 CLA F 8 Stable Arms (18%) Hypertension 0201,68
6 ADL M 40 Stable Diffuse (80%) Glaucoma 0201,31012
7 RNA F 21 Stable Diffuse (80%) No 0201,2301
8 LPA M 10 Stable Face, arms, legs (45%) No 0201,25
9 MBO F 2 Progression Hands, face (18%) Thyroiditis, MsAbd 0201,30
10 RGI M 0.5 Progression Face, right arm (18%) No 26,30
11 MRO F 11 Stable Hands (9%) No 01,2301
12 IMO F 8 Slow progression Hands (9%) Thyroiditis, MsAbd 3301,6601
13 ASC F 14 Stable Hands (9%) No 03,30
14 RCA F 11 Stable Diffuse (80%) No 0301,26
aM, male; F, female.
bThe disease course was de®ned as active vitiligo (newly depigmented lesions during the last three months/progression or slow progression) or stable vitiligo (no recent
depigmented or repigmented lesions in the three months prior to examination).
cNIDDM, non insulin-dependent-diabetes mellitus.
dMsAb, thyroid microsomal antibodies.
Table II.Percentages of circulating TAA-speci®c CTLs in
HLA-A*0201 vitiligo patients and healthy donors
Patient
Vitiligo patients Healthy donors
A2-tetramer+ cellsa A2-tetramer+ cellsa
Melan-A Tyrosinase gp100 Donor Melan-A
1 RSA 0.07 0.10 0.01b 15 GFI 0.13
2 PSA 0.19 0.20 0.04b 16 RBI 0.01b
3 TSC 0.22 0.22 0.00b 17 MSO 0.07
4 SRI 0.09 0.12 ± 18 VPU 0.03b
5 CLA 0.07 0.14 0.04b 19 RMA 0.00b
6 ADL 0.07 0.14 0.02b 20 MES 0.02b
7 RNA 0.09 0.13 0.06b
8 LPA 0.21 0.19 0.01b
9 MBO 0.28 0.21 0.04b
aPercentage of tetramer+ cells relative to total CD8+ T cells.
bPercentage values below the limit of detection.
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lines from patient PSA, ®ve of eight lines from patient LPA and six
of 13 lines from patient MBO could be successfully expanded up to
5 3 106 cells, thus demonstrating a consistent ability of these cells
to proliferate in culture (see Fig 2 for one representative case). At
the end of the culture, cell lines contained from 12- to 470-fold
enriched tetramer+ cells compared with the frequency calculated in
PBMC. We used these lines to assess whether the frequency of
tetramer+ T cells detected in bulk cultures correlated with the
peptide-speci®c cytotoxicity measured by chromium release assay.
We found that the increasing percentage of tetramer+ cells in the
different cultures directly correlated with the speci®c cytotoxic
activity against target cells pulsed with the Melan-A/MART1A27L
peptide (Fig 3), thus con®rming the antigen-speci®city of
tetramer+ cells. On the contrary, the tetramer+ cells found in the
two healthy donors possessed a reduced in vitro expansion potential
following antigen-speci®c stimulation, as was demonstrated by our
inability to obtain a comparable enrichment of tetramer+ cells (not
shown). Importantly, none of the cell lines established from these
healthy donors exhibited lytic activity against target cells pulsed
with the Melan-A/MART1A27L peptide (data not shown).
Next, we examined whether the melanocyte-speci®c CTL could
be capable of lysing HLA-matched melanocyte cell lines from
melanoma patients. T cell clones were generated by limiting
dilution from a Melan-A/MART1-sensitized cell line from patient
PSA. Their ability to lyze both peptide-pulsed target cells and two
different HLA-A*0201-positive melanoma cell lines, which present
the peptide through endogenous processing pathways, was tested.
We found that all CD8+ A2/Melan-A tetramer+ clones were able
to lyze peptide-pulsed targets and ®ve of these exerted a very
ef®cient lytic activity against melanoma cells (Fig 4).
Finally, we examined the skin-homing capacity of Melan-A/
MART1-speci®c CTL clones by analyzing surface expression of
the skin-homing receptor, CLA. Although lower CLA staining
levels were reported for lymphocytes kept in culture than for
uncultured cells (Fuhlbrigge et al, 1997), we found that half of the
clones analyzed (PSA.4.1, PSA.4.7, PSA.4.8, PSA.4.12) expressed
high levels of CLA, about 500-fold over background (data not
shown).
High avidity of melanocyte-speci®c CTL Eight Melan-A/
MART1-speci®c CTL clones established from patient PSA were
selected and their relative avidity measured. Interestingly, the
relative avidity of all clones turned out to be extremely high, with
[nM] 50% comprised between 0.3 and 11 (Fig 5). We found that
clone avidity directly correlated with in vitro anti-melanocytic
activity of CTL, as was demonstrated by the very ef®cient lysis of
melanoma cells we obtained with the ®ve highest avidity clones
(PSA.4.8, PSA.4.7, PSA.4.1, PSA.4.12, PSA.4.33; Figs 4 and 5).
The peptide-speci®c, nontumor-reactive, clones PSA.4.27,
PSA.4.16, and PSA.4.9 exhibited a lower avidity than the ®rst
®ve (Fig 5).
DISCUSSION
This study demonstrates the presence of high frequencies of
melanocyte-speci®c CTL in the peripheral blood of vitiligo
patients. These autoreactive CTL exhibited intact functional
properties, as demonstrated by their consistent ability to undergo
in vitro expansion and to lyze peptide-pulsed antigen-presenting
cells. Notably, they were also capable of lysing HLA-matched
melanoma cell lines more ef®ciently than CTL obtained from
melanoma patients (Palermo et al, 2001). This last feature is
particularly interesting because of the impact that the demonstra-
tion of a superior anti-tumor activity of vitiligo cells might have on
melanoma immunotherapeutical intervention. Lysis of cultured
melanocytes, however, which would be more relevant for vitiligo
pathogenesis, remains to be demonstrated. A proportion of
these anti-melanocyte CTL expressed the skin-homing receptor,
cutaneous lymphocyte antigen CLA, suggesting that circulating
melanocyte-speci®c autoreactive T lymphocytes in vitiligo patients
can be rapidly addressed to the skin. Overall, these ®ndings show a
clear association between the presence of melanocyte-speci®c CTL
and vitiligo, suggesting a pathogenic role for antigen-speci®c T cells
in this disease.
Although we documented a signi®cantly lower frequency of
Melan-A/MART1-speci®c CTL in healthy donors than in vitiligo
patients (p = 0.015), the occasional existence of CTL precursors to
Figure 2. Direct visualization of in vitro expansion of Melan-A/
MART1- and gp100-speci®c precursors from one vitiligo patient.
Total PBMC from patient PSA were stimulated at 3 wk intervals with
peptide-pulsed, irradiated T2 cells as antigen-presenting cells. Peptides
used for pulsing were either A27L or gp100-209M. Cultures were
stained on day 8 after each stimulation with tetramersPE and anti-
CD8FITC monoclonal antibody. Boxed populations, CD8+/tetramer+
cells (frequencies within total CD8+ T cells above each box). On the
right side, number of stimulation cycles.
Figure 1. Enumeration of melanocyte-speci®c CD8+ T cells by
tetramer staining. Cells were gated by forward- and side-scatter for
lymphocytes. Gated populations are plotted as CD8-staining (horizontal
axis) vs tetramer-staining (vertical axis). Each column shows the staining
for a different peptide-loaded HLA-A*0201 tetramer. Boxed populations,
CD8+/tetramer+ cells (frequencies within total CD8+ T cells above each
box). Upper left corner, patient/donor identi®ers.
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this self antigen in healthy blood donors is not fully understood.
They might represent CTL speci®c for environmentally encoun-
tered antigens cross-reacting with human Melan-A/MART1
(Loftus et al, 1996).
An unusual facet of vitiligo is its relation to melanoma. CTL
directed to self antigens shared by normal melanocytes and
melanoma cells are found in both conditions and imply a
breakdown of tolerance, yet the resulting immune reaction is the
opposite. In this respect, reactivity to vitiligo melanocytes may be
regarded as the effective variant of an immune response often
ineffective in melanoma. The mechanisms at the basis of these
opposite effects are not known. An interesting, although contro-
versial, possibility is that vitiligo melanocytes have intrinsic
differences from normal melanocytes with respect to the expression
of immune-related molecules that could explain abnormal immune
response in vitiligo (al Badri et al, 1993a; Hedley et al, 1998).
Upregulation of these surface molecules could enhance antigenicity
of vitiligo melanocytes and elicit an autoimmune response. On the
other hand, this study demonstrates an extremely high avidity in
antigen recognition by the anti-melanocyte CTL clones derived
from one vitiligo patient, as demonstrated by the very low major
histocompatibility complex/peptide densities required to trigger
cytolysis in all eight Melan-A/MART1-speci®c clones analyzed
([nM] 50% between 0.3 and 11). [nM] 50% values reported thus far
for CTL clones, whose reactivity to A*0201-presented, melanoma-
derived self peptides have been documented, widely range from 0.2
to 500 nM (Appella et al, 1995; Valmori et al, 1999a, b). Melan-A/
MART1-speci®c vitiligo clones appeared on the contrary to be
selected for a very narrow range of high avidities. We suggest that
high avidity in antigen recognition might represent a peculiar
property of anti-melanocytic CTL from vitiligo patients that
contribute to their abnormal reactivity. The strong humoral
response described for vitiligo patients might be an important
secondary phenomenon contributing to the fact that autoimmunity
is effective in vitiligo, whereas in melanoma it is not.
The presence of anti-melanocytic CTL exhibiting such a high
avidity was somehow unexpected in terms of self tolerance. In fact,
the most effective way to achieve tolerance to self antigens is
Figure 4. Tumor-reactivity of Melan-A/
MART1-speci®c CTL clones. Eight T cell
clones, derived by limiting dilution from one
Melan-A/MART1-sensitized cell line of patient
PSA, were tested in standard 4 h chromium
release assays for their ability to lyze T2 cells
pulsed with A27L peptide as well as two different,
HLA-matched, melanoma cell lines (501 mel and
213 mel). Lysis of T2 cells pulsed with an
irrelevant peptide is shown as the control. Points
are means of triplicate. Shown is one of several
experiments with similar results.
Figure 3. Correlation between the frequency
of tetramer+ T cells detected in bulk cultures
and the peptide-speci®c cytotoxicity. (a) Five
A27L-speci®c T cell lines established from patient
PSA through peptide-speci®c stimulation were
stained with the A2/Melan-A tetramer. Per-
centages of tetramer+ cells in the different lines
are shown as histograms. (b) The ®ve A27L-
speci®c T cell lines were tested in standard 4 h
chromium release assays for their ability to lyze
HLA-A*0201 T2 cells pulsed with A27L peptide,
at different E/T cell ratios. Lysis of T2 cells pulsed
with an irrelevant peptide is shown as the control.
Points are means of triplicate. Shown is one of
three experiments with similar results.
Figure 5. Avidity of Melan-A/MART1-reactive CD8+ T cell
clones. Eight T cell clones, derived by limiting dilution from Melan-A/
MART1-sensitized cell lines of patient PSA, were tested in standard 4 h
chromium release assays for their ability to lyze HLA-A*0201 T2 cells
pulsed with decreasing concentrations of Melan-A/MART1 A27L
peptide, at an E/T cell ratio of 5 : 1. Avidity ([nM] 50%) was de®ned as
the concentration of peptide required to obtain half maximal lysis of
target cells. At the same E/T cell ratio, lyses of empty T2 cells used as
controls were as follows: PSA.4.7, 3.7%; PSA.4.1, 0.6%; PSA.4.33, 0.9%;
PSA.4.12, 0.4%; PSA.4.8, 0.7%; PSA.4.16, 18%; PSA.4.9, 19%;
PSA.4.27, 15%. Points are means of triplicate. Shown is one of three
experiments with similar results.
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thymic deletion, by which thymocytes recognizing self peptides
with high avidity undergo apoptosis (Kappler et al, 1987; Kisielow
et al, 1988; Surh and Sprent, 1994). Only T cells that recognize self
epitopes with an avidity below a certain threshold are permitted
access to the periphery (Liu et al, 1995; Lee et al, 1999).
Accordingly, it was demonstrated that tolerance to the self antigen
p53 was achieved by selectively eliminating T cells with high
avidity (Hernandez et al, 2000). Vitiligo CTL must have eluded this
central tolerance mechanism. In the periphery, tolerance may be
achieved by a variety of mechanisms, including clonal deletion,
anergy and ignorance. Here, T helper cells become fundamental to
tolerize a wide variety of potentially autoimmune CTL. If
peripheral T help is available, CTL precursors that recognize
antigens are activated, while in the absence of help, they are
tolerized (Guerder and Matzinger, 1992). In vitiligo, however, the
high titers of anti-melanocytic IgG antibodies strongly indicate the
presence of speci®c T helper responses.
The de®nition of the mechanisms by which tolerance is
established to an antigen and those by which tolerance can be
terminated are crucial for understanding the generation of
autoimmune responses. The presence of frequent, high avidity
autoreactive CTL in vitiligo suggests a role for cellular immunity in
the etiology of this disease, but the origin of these cells remains
elusive in the light of the current models of self tolerance. We will
test in the near future the possibility that these autoreactive CTL
are resistant to activation-induced cell death.
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